TP53 and breast carcinoma: Correlation with conventional clinical parameters indicated that FOTS+/TGCT/CSF1+ breast cancers were significantly more likely to be ER negative (52.63%), PR negative (58.62%), Grade 3 (58.11%) and p53 mutant (55.17%) than FOTS-/TGCT/CSF1- breast cancers with ER negative (6.45%), PR negative (12.5%), Grade 3 (9.06%) and p53 mutant (5.24%).